Clinical Trials
12 trialsNCT06499870 2026-06-05
Relugolix and Enzalutamide in Combination With Radiation Therapy for the Treatment of Very High Risk Prostate Cancer, OPTIMAL Trial
Northwestern University
Phase 2 Recruiting
NCT05404139 2026-06-04
DIRECT
University Health Network, Toronto
Phase 2 Recruiting
NCT07287150 2026-06-04
InavoPC
Hoffmann-La Roche
Phase 2 Recruiting
NCT03344211 2026-06-03
Enzalutamide With or Without Radium Ra 223 Dichloride in Patients With Metastatic, Castration-Resistant Prostate Cancer
University of Southern California
Phase 2 Active not recruiting
NCT03899155 2026-06-03
Pan Tumor Rollover Study
Bristol-Myers Squibb
Phase 2 Recruiting
NCT06096870 2026-06-02
Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy
National Institutes of Health Clinical Center (CC)
Phase 2 Recruiting
NCT06228053 2026-06-02
SYNERGY-201
Syntrix Biosystems, Inc.
Phase 2 Recruiting
NCT06632977 2026-06-02
PREDICT
Alliance for Clinical Trials in Oncology
Phase 2 Recruiting
NCT06991556 2026-06-02
An Open-label Study of JSB462 (Luxdegalutamide) in Combination With Abiraterone in Adult Male Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
Novartis
Phase 2 Recruiting
NCT03860987 2026-05-22
Neoadjuvant Androgen Deprivation Therapy Combined With Enzalutamide and Abiraterone Using Multiparametric MRI and 18FDCFPyL PET/CT in Newly Diagnosed Prostate Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT01885949 2026-05-20
Tivozanib + Enzalutamide in Adv Prostate Cancer
Massachusetts General Hospital
Phase 2 Terminated
NCT07592910 2026-05-18
MOMENT
Prostate Cancer Clinical Trials Consortium
Phase 2 Not yet recruiting